Clinical Data Needed For Some Digital Mammography 510(k)s, Panel Says
This article was originally published in The Gray Sheet
Executive Summary
FDA should require some clinical data in 510(k) or de novo 510(k) submissions for new full-field digital mammography devices that substantially change or improve the perception of breast cancer images when compared with prior models, an FDA advisory panel recommended Nov. 17
You may also be interested in...
Digital Mammography Firms Decry Clinical Trial Provisions In Draft Guidance
Digital mammography systems are on the verge of being downclassified to 510(k) status, but imaging firms say the clinical trial requirements proposed in FDA's draft "special controls" guidance for the systems are costly, unnecessary and overly burdensome
Digital Mammography More Accurate Than Film For Younger Women – NEJM
Digital mammography is more accurate than traditional film mammography in women under 50 and women with dense breasts, according to a study slated to appear in the Oct. 27 New England Journal of Medicine
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.